Discovery of Novel Doxorubicin Metabolites in MCF7 Doxorubicin-Resistant Cells

Identification of Human UMP/CMP Kinase 1 as Doxorubicin Binding Target Using Protein Microarray

(2017) Shuxian Chen et al.   SLAS Discovery

Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone

(2016) Roberto Marques Damiani et al.   ARCHIVES OF TOXICOLOGY

Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism

(2015) Fang Zhou et al.   BRITISH JOURNAL OF PHARMACOLOGY

Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells

(2012) X. Ma et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles

(2011) Zhijun Jiao et al.   International Journal of Nanomedicine

Naturally Occurring Variants of Human Aldo-Keto Reductases with Reduced In Vitro Metabolism of Daunorubicin and Doxorubicin

(2010) O. S. Bains et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Limitations in doxorubicin production from Streptomyces peucetius

(2010) Sailesh Malla et al.   MICROBIOLOGICAL RESEARCH

New Developments in Anthracycline-Induced Cardiotoxicity

(2009) A. Mordente et al.   CURRENT MEDICINAL CHEMISTRY

Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver

(2008) N. Kassner et al.   DRUG METABOLISM AND DISPOSITION